A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
Public ClinicalTrials.gov record NCT00483860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Oral Topotecan in Subjects With Cancer and Impaired Renal Function
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally
Study identification
- NCT ID
- NCT00483860
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2007
- Primary completion
- Feb 5, 2012
- Completion
- Feb 5, 2012
- Last update posted
- Nov 12, 2017
2007 – 2012
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Scottsdale | Arizona | 85258 | — |
| GSK Investigational Site | Lebanon | New Hampshire | 03756 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
Recently updated Solid Tumours trials
Other public records listing Solid Tumours. Sorted by last update posted; newest first. Not a recommendation.
- NCT06619509: A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine Active, not recruiting
- NCT07160725: A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors Recruiting
- NCT07224425: A Study of BI 3810944 in Patients With Advanced Cancer Recruiting
- NCT06725758: A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours Recruiting
- NCT07446855: Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours Recruiting
- NCT06581432: Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00483860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2017 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00483860 live on ClinicalTrials.gov.